KDDI Corporation, based in Tokyo, is proud to announce that its ambitious greenhouse gas (GHG) emissions reduction targets have been validated and approved by the Science Based Targets initiative (SBTi). This groundbreaking initiative, in line with the Paris Climate Agreement’s goal of limiting global warming to 1.5 and well-below 2 degrees Celsius, will have a significant and lasting impact on our planet.
Astellas has set its sights on sustainability, making it a cornerstone of its Corporate Strategic Plan 2021. With an ambition to reduce environmental burden, Astellas is determined to strengthen its commitment to sustainability, an effort that will have a lasting and positive impact on the world.
At Astellas, we recognize the importance of environmental sustainability as we strive to grow and develop sustainably as a society. That’s why we are proud to announce our recent SBTi certification, marking a major milestone in our Corporate Strategic Plan 2021. Climate change is a key issue we are determined to address, and this certification is a testament to our commitment to doing our part to mitigate its effects.
Astellas has revised its targets, aiming to go even further in fulfilling its mission. With these changes, the company is now striving to reach higher heights and make a bigger impact in the world.
Astellas is taking ambitious steps to reduce its absolute scope 1 and 2*2 GHG emissions by 63% by FY2030, compared to FY2015 base year, to help reach the global target of 1.5 degrees Celsius.
Astellas is taking bold action to reduce its absolute scope 3 GHG emissions by 37.5% by 2030, compared to the 2015 base year, in order to make a significant contribution to achieving the well-below 2 degrees Celsius target.
At Astellas, we believe that to build a better global society, we must stay mindful of ESG (environmental (E), social (S), governance (G)) in our initiatives. That’s why we are continuing to expand our sustainability activities and make more information available to the public, all in line with our overall aim of improving sustainability both inside and outside our organization.
Science Based Targets initiative
The Science Based Targets initiative (SBTi) is a powerful collaboration between the CDP, the United Nations Global Compact, the World Resources Institute (WRI) and the World Wide Fund for Nature (WWF) that drives ambitious climate action in the private sector. Through the SBTi, companies are given the opportunity to set science-based greenhouse gas emissions reduction targets that have a real impact on the planet.
The calculation of greenhouse gas emissions is a critical factor in understanding and addressing climate change. Range of GHG emission calculation provides a comprehensive approach to understanding the causes and impacts of global warming, from the local to the global level. This calculation can help inform initiatives to reduce emissions, as well as provide insight into the current and future effects of climate change.
Uncover the GHG emissions from your own energy use! Understand the direct emissions of greenhouse gases from the fuels used in your own home.
The indirect emissions of greenhouse gases (GHGs) resulting from the consumption of purchased electricity can have a significant impact on the environment. With an ever-increasing demand for electricity, it is essential to consider the consequences of our electricity consumption and take steps to reduce our carbon footprint.
The emissions of Greenhouse Gases (GHG) throughout the supply chain of business activities, such as the procurement of raw materials and the use of products, are a critical factor to consider for any organization’s sustainability goals. Understanding and managing the environmental impacts of these activities is an essential part of any company’s commitment to sustainability.
Astellas Pharma Inc. is a global leader in the field of pharmaceuticals, reaching more than 70 countries worldwide. We strive to make a difference in the world by creating innovative treatments for diseases with unmet medical needs, through our Focus Area Approach. Our approach focuses on both Biology and Modality, as we strive to identify new ways to develop drugs that will make a positive impact on people’s lives.
At Astellas, we are proud to be leading healthcare change by creating Rx+® healthcare solutions. Combining our expertise and knowledge with the latest cutting-edge technology from external partners, we are revolutionizing the way patients receive care. Our mission is to provide VALUE to every patient, bringing innovative science to life to make a lasting impact on healthcare.
Astellas has made forward-looking statements about its future performance, based on its current assumptions, beliefs, and the information currently available to it. However, there are a number of risks and uncertainties that could cause actual results to differ materially from these statements. These include changes in general economic conditions, changes in laws and regulations, currency exchange rate fluctuations, delays in new product launches, and the inability of Astellas to market existing and new products effectively. Additionally, there is a risk of third parties infringing Astellas’ intellectual property rights. Despite these risks, Astellas remains committed to researching and developing products that will be accepted by customers in highly competitive markets.
This press release contains information about pharmaceutical products, including those currently in development, but it is important to note that this information should not be seen as an advertisement or medical advice.